A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Glycine; Sivelestat

Criteria

Inclusion Criteria

• show evidence of acute lung injury

• be on mechanical ventilation

Exclusion Criteria

• have undergone certain organ transplants

• have severe underlying medical problems

• be unlikely to survive

• be pregnant or breast-feeding